非小细胞肺癌组织中T细胞免疫球蛋白区黏蛋白-3、程序性死亡因子-1及程序性因子配体1的表达分析  

Expression of TIM-3,PD-1 and PD-L1 in non-small cell lung cancer

作　　者：梁乐乐 王鹏[3] 刘俊霞[3] 董玉 郭华[2] LIANG Lele;WANG Peng;LIU Junxia;DONG Yu;GUO Hua(Department of Emergency,Shaanxi Provincial People’s Hospital,Xi’an 710068,China)

机构地区：[1]陕西省人民医院急诊科,陕西西安710068 [2]西北工业大学医院,陕西西安710109 [3]西安市中心医院呼吸与危重症医学科,陕西西安710004

出　　处：《陕西医学杂志》2021年第10期1227-1230,共4页Shaanxi Medical Journal

基　　金：陕西省重点研发计划项目(2018SF-062)。

摘　　要：目的:分析非小细胞肺癌内T细胞免疫球蛋白区黏蛋白-3(TIM-3)、程序性死亡因子-1(PD-1)及程序性因子配体1(PD-L1)的表达情况。方法:选取非小细胞肺癌患者67例,探究患者临床病例特征和TIM-3、PD-1及PD-L1指标状况。结果:观察组TIM-3、PD-1、PD-L1诊断时阳性率高于对照组,差异有统计学意义(均P<0.05);男性、女性,不同年龄患者TIM-3、PD-1等指标阳性率并无统计学差异(均P>0.05);无淋巴结、无转移、中高级患者、Ⅱ期患者PD-1、TIM-3等指标阳性率差异有统计学意义(均P<0.05)。结论:随着非小细胞肺癌患者疾病持续恶化,TIM-3、PD-1及PD-L1指标可快速提升,其中TIM-3、PD-L1可用于判定患者疾病发展,为患者疾病治疗提供新方向。Objective:To analyze the expression of T cell immunoglobulin domain mucin-3(TIM-3),programmed death factor-1(PD-1)and Programmed factor ligand 1(PD-L1)in non-small cell lung cancer.Methods:67 patients with non-small cell lung cancer were selected to explore the clinical characteristics and TIM-3,PD-1 and PD-L1 indicators.Results:The positive rates of TIM-3,PD-1 and PD-L1 in the observation group were higher than those in the control group(all P<0.05).There was no significant difference in the positive rates of TIM-3,PD-1 and other indicators of different genders and ages(all P>0.05).There was significant difference in the positive rates of PD-1,TIM-3 and other indicators among patients without lymph node metastasis,middle and advanced stage,and patients of stageⅡ(all P<0.05).Conclusion:As the disease of patients with non-small cell lung cancer continues to worsen,TIM-3,PD-1 and PD-L1 levels can be rapidly increased.Among them,TIM-3 and PD-L1 can be used to determine the disease development and provide new direction for the treatment of patient’s disease.

关 键 词：非小细胞肺癌 T细胞免疫球蛋白区黏蛋白-3 程序性死亡因子-1 程序性因子配体1 淋巴结转移 TNM分期 性别 

分 类 号：R734.2[医药卫生—肿瘤]